- Home
- BTBD vs IMRN Comparison
BTBD vs IMRN Comparison
Compare BTBD & IMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BTBD
- IMRN
- Stock Information
- Founded
- BTBD 1987
- IMRN 1994
- Country
- BTBD United States
- IMRN Australia
- Employees
- BTBD N/A
- IMRN N/A
- Industry
- BTBD Restaurants
- IMRN Biotechnology: Pharmaceutical Preparations
- Sector
- BTBD Consumer Discretionary
- IMRN Health Care
- Exchange
- BTBD Nasdaq
- IMRN Nasdaq
- Market Cap
- BTBD 9.1M
- IMRN 9.2M
- IPO Year
- BTBD 2021
- IMRN N/A
- Fundamental
- Price
- BTBD $1.69
- IMRN $1.93
- Analyst Decision
- BTBD
- IMRN Strong Buy
- Analyst Count
- BTBD 0
- IMRN 1
- Target Price
- BTBD N/A
- IMRN $5.00
- AVG Volume (30 Days)
- BTBD 5.5M
- IMRN 47.9K
- Earning Date
- BTBD 11-12-2025
- IMRN 08-29-2025
- Dividend Yield
- BTBD N/A
- IMRN N/A
- EPS Growth
- BTBD N/A
- IMRN N/A
- EPS
- BTBD N/A
- IMRN N/A
- Revenue
- BTBD $14,533,449.00
- IMRN $4,777,422.00
- Revenue This Year
- BTBD N/A
- IMRN N/A
- Revenue Next Year
- BTBD N/A
- IMRN N/A
- P/E Ratio
- BTBD N/A
- IMRN N/A
- Revenue Growth
- BTBD 1.58
- IMRN 48.63
- 52 Week Low
- BTBD $1.00
- IMRN $1.50
- 52 Week High
- BTBD $5.60
- IMRN $2.87
- Technical
- Relative Strength Index (RSI)
- BTBD 45.69
- IMRN 59.97
- Support Level
- BTBD $1.61
- IMRN $1.80
- Resistance Level
- BTBD $4.50
- IMRN $1.93
- Average True Range (ATR)
- BTBD 0.38
- IMRN 0.07
- MACD
- BTBD -0.06
- IMRN 0.01
- Stochastic Oscillator
- BTBD 2.77
- IMRN 99.45
About BTBD BT Brands Inc.
BT Brands Inc operates and owns a fast-food restaurant called Burger Time. The company also operates in Minnesota as a franchisee of Dairy Queen. It offers a variety of burgers and other affordably priced foods such as chicken sandwiches, pulled pork sandwiches, chicken chunks, side dishes, and soft drinks.
About IMRN Immuron Limited
Immuron Ltd is a commercial and clinical-stage biopharmaceutical company focused on the development and commercialization of a novel class of immunomodulator polyclonal antibodies to treat liver diseases, infectious diseases and other immune-mediated diseases, such as colitis. The company's product, IMM-124E, is a proprietary immunomodulatory agent targeted at GI immune-mediated diseases including fatty liver diseases. The company functions in two segments namely, Research and Development and Hyperimmune products.